Apex Healthcare Berhad

 
  DOWNLOAD ANNUAL REPORT
  FINANCIAL RESULTS
 

Manufacturing

Xepa-Soul Pattinson

Apex Healthcare Group's wholly-owned manufacturing division Xepa-Soul Pattinson (Malaysia) Sdn Bhd operates under the Xepasp name. Xepasp produces high quality off-patent pharmaceuticals for domestic and export markets.

Xepasp laboratories develop products – formulating, designing and validating – that are then manufactured to exacting standards. From there, Xepa’s marketing team brands, positions, promotes and handles sales of the products to private and government-run clinics, pharmacies and hospitals, within Malaysia and the region.

Xepa's plant is at a 10-acre site in Cheng Industrial Estate in Malaysia and comprises 180,000 square feet of development laboratories, production floors, warehouses and offices.

The Xepa range of products include cough mixtures and antihistamines, anti-infectives, anti-diabetics, anti-hypertensives, neuromuscular agents, analgesics, dermatologicals and ophthalmologicals in the form of tablets, capsules, oral liquid and suspension, creams and sterile eyedrops. The top-selling products include Bena and Sedilix, which are market leaders in the cough and cold category.

Xepa employs world-class (PIC/S) Good Manufacturing Practice. Its plant is ISO 9001:2015 certified for its Quality Management System and the laboratory is ISO/IEC 17025 certified. It is also certified for ISO 13485 that represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.

In September 2017, Xepa was awarded a Certificate Of GMP Compliance Of A Manufacturer (also known as EU GMP Certificate) by the national competent authority of Hungary on behalf of the European Medicines Agency. The scope of the certification encompasses a wide spectrum of manufacturing operations of human medicinal products, namely sterile (eye drops) and non-sterile products (solids, semi-solids and liquids), packaging (both primary and secondary) and quality control testing (microbiological and chemical/physical). This EU GMP certification is a key milestone in Xepa's strategy for sustainable long-term growth.

Over the next few years, Xepa will continuously embark on upgrading and expansion of its plant and facilities, which will keep it in the forefront of the regional market for years to come. Its new Oral Solid Dosage manufacturing facility (SPP NOVO) located at Cheng Industrial Estate Melaka which is expected to be commissioned in 2018 is a vital infrastructure towards this end.

www.xepasp.com

Straits Apex

Apex Healthcare Group’s orthopaedic devices business, Straits Apex Sdn Bhd, operates under the names of ABio Ortho and Straits Ortho. 

In 2013, Apex Healthcare Group made its foray into the business of manufacturing orthopaedics devices for the global market through ABio Ortho. A year later, the Group acquired a 40% equity in Straits Apex Sdn Bhd which in turn owns 87% of Straits Ortho. All the Group’s orthopaedics businesses are now aligned under a holding company, Straits Apex Sdn Bhd. The orthopaedics segment adds a new engine of growth in addition to the Group’s existing pharmaceutical manufacturing and distribution businesses, increasing opportunities while diversifying risk.

The orthopaedics business contract manufactures surgical grade orthopaedic devices, components and surgical instruments. Orthopaedic components (e.g. screws, plates, implants, intra-medullary nails, pins, external fixators) are used in the surgical treatment of musculoskeletal disorders resulting from trauma, disease, injuries or deformities.

The global market of orthopaedic components was worth US$ 46.6 billion in 2015. 80% of these devices are consumed in the developed markets of USA, Europe and Japan. Currently, the global market is largely dominated by ten multinational orthopaedic companies. Due to rising costs, these companies are relying increasingly on certified contract manufacturers outside Western Europe and the United States for production. The formation of Straits Apex creates a platform for the Group to take advantage of the steady growth of global orthopaedics market.

www.straitsortho.com.my

XEPA PLANT

Xepa's plant is at a 10-acre site in Cheng Industrial Estate in Malaysia and comprises 180,000 square feet of development laboratories, production floors, warehouses and offices.

Representative Office in Ho Chi Minh City, Vietnam